Switching from Warfarin to Rivaroxaban: INR Requirements
Your INR should be ≤2.0 before starting rivaroxaban (Xarelto) after discontinuing warfarin (Coumadin).
Practical Switching Protocol
When transitioning from warfarin to rivaroxaban, follow this approach:
- Stop warfarin and wait for the INR to fall to ≤2.0 before initiating rivaroxaban 1
- Check INR daily after stopping warfarin until it reaches the target threshold
- Start rivaroxaban once INR ≤2.0 is confirmed
- Do not overlap the two medications, as this creates additive anticoagulant effects
Why This Matters: The Overlap Risk
The evidence shows that combining warfarin with rivaroxaban creates a supra-additive effect on PT/INR during the initial transition period. Research demonstrates that when rivaroxaban is started while warfarin is still active, the PT can prolong up to 4.39-fold compared to baseline—significantly higher than either drug alone 2. This excessive anticoagulation substantially increases bleeding risk without improving thrombotic protection.
Timeline Expectations
Based on warfarin's pharmacokinetics 3:
- Half-life: 20-60 hours (mean ~40 hours)
- Factor VII (shortest half-life): 4-6 hours
- Factor II (longest half-life): 60 hours
- Typical waiting period: 3-5 days after stopping warfarin for INR to fall below 2.0
The exact time depends on your baseline INR, warfarin dose, age, liver function, and genetic factors (CYP2C9 and VKORC1 polymorphisms).
Critical Safety Considerations
During the first 60 days after switching, there is a temporarily increased risk of adverse events, even when done correctly 4. This early risk period requires:
- Close monitoring for bleeding or thrombotic symptoms
- Ensuring proper rivaroxaban dosing based on renal function (15 mg daily if CrCl 15-50 mL/min; 20 mg daily if CrCl >50 mL/min) 1
- Maintaining anticoagulation continuously—do not create gaps in coverage
Common Pitfalls to Avoid
- Starting rivaroxaban too early (INR still >2.0): Creates dangerous over-anticoagulation with markedly elevated bleeding risk
- Waiting too long (allowing INR to fall to 1.0): Creates a gap in anticoagulation coverage, increasing stroke/thrombosis risk
- Using PT/INR to monitor rivaroxaban: Once on rivaroxaban, PT/INR is no longer a reliable monitoring tool—rivaroxaban does not require routine coagulation monitoring
Special Populations
- Elderly patients (≥80 years): May have slower warfarin clearance and require longer waiting periods 3
- Impaired renal function: Affects both warfarin elimination and rivaroxaban dosing requirements 1
- Recent thrombotic events: Ensure continuous anticoagulation coverage—consider bridging with low molecular weight heparin if INR falls below therapeutic range before rivaroxaban can be started
The INR threshold of ≤2.0 balances the competing risks of thrombosis (if you wait too long) versus bleeding (if you start too early while warfarin effects persist).